Structure Therapeutics Inc.
GPCR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GPCR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule GPCR-targeted therapies for metabolic and pulmonary diseases, with its lead candidate aleniglipron in Phase 2/3 for chronic weight management and no approved products or revenue to date.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.38B
Cash Runway
32.4 moLead Asset
ACCG-2671 (Phase 1)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 19 clinical trials · 4 catalysts for Structure Therapeutics Inc..
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule GPCR-targeted therapies for metabolic and pulmonary diseases, with its lead candidate aleniglipron in Phase 2/3 for chronic weight management and no approved products or revenue to date.
- No product candidates approved for sale; no revenue generated from products as of 2026-08-06 [sec_mda].
- Net loss of $106.2M for the six months ended 2026-06-30 (from structured financials) [sec].
- Cash & equivalents of $272.6M as of 2026-06-30 (from structured financials) [sec]; shareholders' equity $1,516.4M [sec].
- Accumulated deficit of $652.4M as of 2026-06-30 [sec_mda].
- Cash runway estimated to fund operations and key clinical milestones through end of 2028, excluding pre-commercialization costs [sec_mda · as of 2026-02-26].
What works
- Cash runway through 2028 provides a multi-year development horizon without near-term financing pressure [sec_mda · as of 2026-02-26].
- Lead candidate aleniglipron is advancing in a Phase 2/3 registrational program for chronic weight management, a large and growing market [sec_mda · as of 2026-02-26].
- Strong balance sheet with $1,516.4M in shareholders' equity as of 2026-06-30 [sec] supports ongoing R&D and clinical trials.
- Multiple clinical-stage programs (aleniglipron, IMPACT-AML) diversify pipeline risk across metabolic and oncology indications [catalyst timeline].
What to weigh
- No approved products or revenue; company is entirely pre-commercial and dependent on successful development and regulatory approval [sec_mda · as of 2026-08-06].
- Significant and increasing operating losses: net loss of $106.2M in H1 2026 alone [sec] and accumulated deficit of $652.4M [sec_mda].
- Clinical-stage biotech carries inherent risk of trial failure, regulatory delay, or unfavorable data; aleniglipron Phase 2 topline not expected until late 2026 [catalyst timeline].
- Cash & equivalents of $272.6M (as of 2026-06-30) is substantially lower than the $1,446.2M reported at year-end 2025, indicating rapid cash burn [sec_mda].
From the filings
Quoted directly from source documents.
No product revenue and no approved products
“We do not have any product candidates approved for sale and have not generated any revenue from our products.”
SEC MD&A · August 6, 2026
Net loss and accumulated deficit
“We had net losses of $182.1 million and $108.5 million in the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, we had an accumulated deficit of $652.4 million.”
SEC MD&A · August 6, 2026
Cash runway through 2028
“Based on our current business plan, we estimate that our existing cash, cash equivalents and short-term investments will be sufficient to fund our projected operations and key clinical milestones through the end of 2028.”
SEC MD&A · February 26, 2026
Cash position at year-end 2025
“As of December 31, 2025, we had cash, cash equivalents and short-term investments of $1,446.2 million.”
SEC MD&A · February 26, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · aleniglipron — Phase 2 Readout: aleniglipron — Topline data from the Phase 2 study of aleniglipron will provide initial efficacy and safety signals for the lead candidate.
- 2028-01-01 · Phase3_Topline — Phase 3 Topline: IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. — Topline results from the Phase 3 IMPACT-AML trial will assess the candidate's efficacy in relapsed/refractory AML.
- 2028-11-01 · Phase3_Topline — Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Effi — Topline data from a pivotal Phase 3 study will evaluate long-term efficacy of a candidate (likely aleniglipron) in chronic weight management.
- 2028-11-01 · Phase3_Topline — Phase 3 Topline: A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and — Topline results from another long-term Phase 3 study will provide additional efficacy and safety data for the registrational program.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Company has no approved products and no product revenue; entirely dependent on clinical success and regulatory approval [sec_mda · as of 2026-08-06].
- Significant operating losses — Net loss of $106.2M in H1 2026 and accumulated deficit of $652.4M as of 2026-06-30 [sec, sec_mda].
- Rapid cash burn — Cash & equivalents fell from $1,446.2M (Dec 2025) to $272.6M (Jun 2026), indicating high burn rate [sec_mda, sec].
- Clinical trial and regulatory risk — Lead candidate aleniglipron has not yet reported Phase 2 topline data (expected late 2026); trial failure or delay could impair pipeline [catalyst timeline].
What to watch
- Phase 2 topline data for aleniglipron expected by end of 2026 [catalyst timeline].
- Cash burn rate and any additional financing or partnership activities [sec_mda].
- Progress of Phase 3 registrational program for aleniglipron in chronic weight management [sec_mda · as of 2026-02-26].
- Any updates on the IMPACT-AML Phase 3 trial for relapsed/refractory AML [catalyst timeline].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Structure Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Structure Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
32.4 months
D/E 0.05 · 0% dilution
Lead: Phase 3
5 candidates
4 upcoming, next in ~123d
0 buys · 4 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
197
Total value held
$2.88B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 8,403,449 | $405.0M |
| wellington management group llp | 7,260,287 | $349.9M |
| janus henderson group plc | 5,505,798 | $265.5M |
| deep track capital, lp | 4,279,848 | $206.3M |
| bvf inc/il | 3,459,358 | $166.7M |
| morgan stanley | 2,305,457 | $111.1M |
| principal financial group inc | 1,753,764 | $84.5M |
| driehaus capital management llc | 1,577,356 | $76.0M |
| orbimed advisors llc | 1,475,403 | $71.1M |
| american century companies inc | 1,438,031 | $69.3M |
Showing top 10 of 197 institutional holders of Structure Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 10.8%
- Days to cover
- 5.7
- Shares short
- 5,756,688
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GPCR short interestFrequently asked questions
What is the AI investment thesis for Structure Therapeutics Inc.?
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule GPCR-targeted therapies for metabolic and pulmonary diseases, with its lead candidate aleniglipron in Phase 2/3 for chronic weight management and no approved products or revenue to date.
What is Structure Therapeutics Inc.'s lead drug candidate?
Structure Therapeutics Inc.'s most advanced tracked candidate is ACCG-2671 (Phase 1) for obesity.
What is Structure Therapeutics Inc.'s next catalyst?
Structure Therapeutics Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: aleniglipron" — expected December 31, 2026.
Who is the CEO of Structure Therapeutics Inc.?
Dr. Raymond C. Stevens Ph.D. is the chief executive officer of Structure Therapeutics Inc. (GPCR).
Where is Structure Therapeutics Inc. headquartered?
Structure Therapeutics Inc. (GPCR) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.